Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
about
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisImmune checkpoint inhibitor therapy associated hypophysitisToxicities of Immunotherapy for the PractitionerHypophysitis: Evaluation and Management.Targeting precision medicine toxicity: recent developments.Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Pituitary Medicine From Discovery to Patient-Focused Outcomes.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma.In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis.Ipilimumab-induced hypophysitis: review of the literature.Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Prospects for the use of ipilimumab in treating advanced prostate cancer.Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.Ipilimumab in melanoma.Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapiesThe confused oncologic patient: a rational clinical approach.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesResponses to immune checkpoint inhibitors in nonagenarians.Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis.Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.[Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.Pituitary Antibodies in an Adolescent with Secondary Adrenal Insufficiency and Turner Syndrome.Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery.Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies.Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
P2860
Q26785746-E4344A27-87ED-4EDA-8353-2B3A1BDB0DD0Q26827140-F790F199-CD7A-46E7-8E79-5665880FACAEQ27008140-B2391145-AC1A-4DDF-BF5B-AF564DE41211Q33801229-A11D1983-558E-4920-9611-54DE036355AEQ35019470-0D0F60EC-D089-41F5-B11A-0A1877665793Q35074088-CACFBFA2-C6BA-45E9-B7A5-CB7D544E861EQ35102181-B6D2CC1E-079B-4683-8EB8-1D34182E943AQ36132702-147CD8E0-F2D0-47AE-A59B-3F30570766FCQ36173638-C8031B88-6E40-4384-814C-97F1652AABA1Q36716025-FF9DBE19-DF0E-4A46-85D9-4D58EDE3D2EFQ37131014-EBE54BF3-165D-4C56-B531-2B64BEA1CB3EQ37158935-B0E2EE7A-A2EC-4BF5-9E59-441FD820A6D2Q37681734-A8343E2B-E59F-4C75-9CB4-8FE69E90F02EQ38469194-CD9DC0F9-BC6F-4CE1-A0A9-18D7E10F276CQ38502692-8B7E95F4-9783-494A-8177-BF68CF125A1DQ38549542-58A94345-9B06-45C3-91BE-F3A500882738Q38677420-13DAE4D0-8F4A-4144-A2B1-F6F48F192CFDQ38699309-3F63B38D-04ED-4AAC-B65B-01C375964D40Q38735236-DA20A8BA-EFE5-4620-8927-A8ECB03ED4CDQ38783026-6DAC85AD-05E8-40D4-9895-FD2E7F2A178AQ38801272-613ACD81-421A-4923-BF1B-CC1F40C0B9A5Q38893697-C8B19023-FC73-4513-AA6F-2A12E991B29AQ38932440-86E6634E-2B3E-4EA1-8C0B-B036502CD2FDQ38965811-B27414CA-F728-4E14-83D1-4C140C844AF0Q39010566-79DAFD5C-975D-4B87-B46B-6A697D2B9E0FQ39079683-3B785810-2F96-4E47-837E-9B2735CDDBB8Q39148284-32C94563-72EE-40DE-B3EA-F6D03C25715AQ39441719-2E26E41B-1389-4AF1-87F9-66CA11CB8C7EQ40124225-0EA7C507-7855-4DD5-BE92-35102F0E91C9Q40302759-E4022962-4DF0-4038-ABAF-C2490026807AQ41669891-DA8A5E4D-9FA1-47FA-8B87-ED703F290367Q42378748-A9551D87-159F-42ED-84D3-5BEA706760FDQ45839919-C0B82FD5-E149-4F65-90A8-CD124CBB05EDQ47106542-68EAD23F-43B5-412E-93ED-6FC3585AF311Q47141466-19D79102-38B8-4ADB-8D30-ECB4F6831261Q47906372-7533D680-7C71-4CCF-AEF1-63DE6600B1A3Q48289680-55D79DFE-9184-4034-B3DE-6F64302DCAA6Q50355383-059AC81C-D34A-4BDC-A977-F3F006B8FB9FQ50420603-B02A7785-7DF2-4FDC-AF1D-6F62F18CC622Q51307035-FD3F721F-D7F2-4323-B621-6E1ECDEAEB94
P2860
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@ast
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@en
type
label
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@ast
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@en
prefLabel
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@ast
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@en
P2093
P356
P1476
Ipilimumab-induced hypophysiti ...... ents with metastatic melanoma.
@en
P2093
Alexander T Faje
Donald Lawrence
Lisa Nachtigall
Nicholas A Tritos
Riley Fadden
Ryan Sullivan
P304
P356
10.1210/JC.2014-2306
P407
P577
2014-07-31T00:00:00Z